Chaim Lebovits - Apr 17, 2024 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role
President & CEO
Signature
/s/ Chaim Lebovits
Stock symbol
BCLI
Transactions as of
Apr 17, 2024
Transactions value $
$131,411
Form type
4
Date filed
4/19/2024, 06:05 AM
Previous filing
Mar 13, 2024
Next filing
Apr 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCLI Common Stock Award $70.9K +130K +21.72% $0.55 728K Apr 17, 2024 Direct F1
transaction BCLI Common Stock Award $60.5K +115K +15.8% $0.53 844K Apr 18, 2024 Direct F2
holding BCLI Common Stock 2M Apr 17, 2024 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 67,053 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.